Literature DB >> 9551914

Role of proteasomes in T cell activation and proliferation.

X Wang1, H Luo, H Chen, W Duguid, J Wu.   

Abstract

The role of proteasomes in T cell activation, proliferation, and apoptosis was investigated using a proteasome-specific inhibitor lactacystin (LAC). Inhibition of the proteasome activity by LAC repressed the mitogen-induced T cell proliferation. The proteasome activity was definitively required for the T cells to progress from the G0 to S phase. It was necessary to optimize the progress from the G1/S boundary to the G2/M phase, but not for the progress from the G2/M phase to the next G1 phase. Probably as a result of a blockage of cell cycle progress, the cycling, but not the resting, T cells underwent apoptosis when treated with LAC. Mechanistically, we have found that cyclin-dependent kinase-2 (CDK2) and the cyclin E-associated kinase (largely CDK2), but not CDK4, in the G1 phase were strongly inhibited by LAC. This could be an important mechanism for the proteasome to regulate the cell cycle. The degradation of cyclin E in the late G1 and early S phases was dependent on the proteasome, although it was unlikely that this accounted for the observed inhibition of T cell proliferation. There was a reduced decay of p27Kip1 in the late G1 phase when the proteasome activity was suppressed, and this might be a contributing mechanism for the observed inhibition of CDK2 activity. Interestingly, p21Cip1 was up-regulated during the G1 phase, and the up-regulation was inhibited by LAC. Our study shows that the proteasome plays pivotal roles in regulating T cell activation and proliferation, and its effect is probably exerted through multiple mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551914

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Differential effects of lactacystin on cytokine production in activated Jurkat cells and murine splenocytes.

Authors:  Cheryl E Rockwell; Nilofer Qureshi
Journal:  Cytokine       Date:  2010-04-27       Impact factor: 3.861

2.  Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

Authors:  Cord Naujokat; Carsten Berges; Alexandra Höh; Hubert Wieczorek; Dominik Fuchs; Jörg Ovens; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel
Journal:  Immunology       Date:  2006-11-03       Impact factor: 7.397

Review 3.  Strategies to modulate immune responses: a new frontier for gene therapy.

Authors:  Valder R Arruda; Patricia Favaro; Jonathan D Finn
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

Review 4.  Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.

Authors:  Kyung Bo Kim; Craig M Crews
Journal:  J Med Chem       Date:  2008-04-05       Impact factor: 7.446

5.  Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction.

Authors:  Jonathan D Finn; Daniel Hui; Harre D Downey; Danielle Dunn; Gary C Pien; Federico Mingozzi; Shangzhen Zhou; Katherine A High
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

Review 6.  Advances in immunosuppression for renal transplantation.

Authors:  Antoine Durrbach; Helene Francois; Severine Beaudreuil; Antoine Jacquet; Bernard Charpentier
Journal:  Nat Rev Nephrol       Date:  2010-02-02       Impact factor: 28.314

7.  Regulators of the proteasome pathway, Uch37 and Rpn13, play distinct roles in mouse development.

Authors:  Amin Al-Shami; Kanchan G Jhaver; Peter Vogel; Carrie Wilkins; Juliane Humphries; John J Davis; Nianhua Xu; David G Potter; Brenda Gerhardt; Robert Mullinax; Cynthia R Shirley; Stephen J Anderson; Tamas Oravecz
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

8.  Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.

Authors:  John Koreth; Kristen E Stevenson; Haesook T Kim; Michael Garcia; Vincent T Ho; Philippe Armand; Corey Cutler; Jerome Ritz; Joseph H Antin; Robert J Soiffer; Edwin P Alyea
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

9.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

10.  A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.

Authors:  Alex F Herrera; Haesook T Kim; Bhavjot Bindra; Kyle T Jones; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Sarah Nikiforow; Bruce R Blazar; Jerome Ritz; Joseph H Antin; Robert J Soiffer; John Koreth
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.